Drug Database
KE

ketoprofen (KefenTech / ketoprofen, Jeil / Kefen patch)

✓ Approved

Jeil Pharmaceutical · PTGS1 · 小分子

什么是 ketoprofen?

ketoprofen 是一种小分子,由Jeil Pharmaceutical研发。该药已获批,用于治疗相关适应症,给药途径:Transdermal。

药物档案

商品名KefenTech, ketoprofen, Jeil, Kefen patch
公司Jeil Pharmaceutical
药物类别小分子
分子靶点PTGS1, PTGS2
给药途径Transdermal
状态Approved

作用机制

分子靶点

ketoprofen 作用于 2 个分子靶点:

PTGS1prostaglandin-endoperoxide synthase 1 (COX3, PCOX1)
PTGS2prostaglandin-endoperoxide synthase 2 (GRIPGHS, hCox-2)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

ketoprofen 针对 3 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Musculoskeletal and connective tissue disordersBursitis✓ Approved
Musculoskeletal and connective tissue disordersOsteoarthritis✓ Approved
Musculoskeletal and connective tissue disordersTendonitis✓ Approved

相关研究文献

PubMedAnalytical methods : advancing methods and applications2026-11-18

A DoE-optimized QuEChERS-HRMS method for the simultaneous determination of pesticides and pharmaceuticals in dairy products.

Boti Vasiliki V, Kobothekra Vasiliki V, Nannou Christina C, Albanis Triantafyllos T

Pesticides and pharmaceuticals may co-occur as residues in milk, yet the two classes frequently differ in polarity and stability, so a single sample preparation condition rarely suits both and they are conventionally determined by separate, class-specific protocols. This study presents a QuEChERS-high-resolution mass spectrometry (HRMS) method that reconciles these conflicting requirements within one workflow for the simultaneous determination of ten pesticides and four pharmaceuticals in dairy products. Salting-out and clean-up options were first compared, showing that carbon-based clean-up is incompatible with the aromatic pharmaceuticals; the amounts of sodium acetate, PSA and acetic acid were then optimized by a design-of-experiments approach (Plackett-Burman screening followed by a central composite design and response-surface modelling), yielding a single acidified acetate/PSA condition, with residual matrix effects compensated by matrix-matched calibration. Validation in milk gave recoveries of 66-117% at 10 and 50 µg kg-1 (RSD ≤ 14.9%), coefficients of determination (R2) of 0.9915-0.9996 and limits of quantification of 2.7-25 µg kg-1. Application to 41 dairy products from the Greek market showed that quantifiable residues were infrequent; ketoprofen in two samples (up to 15.0 µg kg-1), trimethoprim and myclobutanil in one each, and coumaphos only at trace level, with the quantified veterinary-drug residues below their EU MRLs. By consolidating two compound classes that are usually determined by separate protocols into one DoE-optimized procedure that also permits retrospective suspect and non-target screening, the method provides a practical tool for dairy-safety monitoring.

PMID 43049679
阅读全文 →
PubMedLymphology2026-11-09

Pharmacological Treatment of Lymphedema:State of The Art.

Chatzelas D A DA, Kantzas M I MI, Dimakakos E P EP

Lymphedema is a chronic, progressive disorder characterized by impaired lymphatic transport, persistent inflammation, adipose deposition, and tissue fibrosis. Although complete decongestive therapy remains the cornerstone of management, it does not directly modify the biological mechanisms responsible for disease progression. This review summarizes current evidence on the pharmacological treatment of primary and secondary lymphedema. A comprehensive literature search of MEDLINE/PubMed, Scopus, Web of Science, and the Cochrane Library was performed from database inception to June 30, 2026, supplemented by manual reference screening. Experimental studies, clinical trials, observational studies, systematic reviews, and consensus documents evaluating pharmacological, biological, gene-based, and regenerative therapies were included. Conventional agents, including diuretics, benzopyrones, flavonoid-derived veno-active drugs, selenium, and doxycycline, have demonstrated limited or inconsistent clinical benefit. More recently, advances in lymphatic biology have identified promising therapeutic targets, including ketoprofen, selective leukotriene B4 inhibition, topical tacrolimus, interleukin-4/interleukin-13 blockade, trans-forming growth factor-β inhibition, glucagon-like peptide-1 receptor agonists, vascular en-dothelial growth factor-C gene therapy, and cell-based regenerative approaches. Future progress will depend on adequately powered, phenotype-specific clinical trials integrating emerging pharmacological therapies with established conservative and surgical man-agement.

PMID 43003070
阅读全文 →
PubMedInternational journal of pharmaceutical compounding2026-10-31

Topical Ketoprofen 5%, Amitriptyline HCL 5%, and Lidocaine 5% Compounded in VersaPro Cream for Diabetic Peripheral Neuropathy: A Case Report.

McSwan Joyce J, Haiub Halema H

Peripheral neuropathy is a common complication of type 1 and type 2 diabetes, often resulting in severe pain that significantly impacts the quality of life. This case report describes the treatment of a 56-year-old female patient with severe peripheral neuropathic pain in the lower extremities due to type 1 diabetes after pain persisted while using conventional therapy. The patient was prescribed a compounded topical cream containing Ketoprofen 5%, Amitriptyline HCL 5%, and Lidocaine 5% in VersaPro Cream Base to help address symptoms of diabetic peripheral neuropathy in addition to her systemic medications. Over an 8-week treatment period, the patient reported significant reductions in pain intensity and improved functional outcomes, including sleep quality and mobility. This case highlights the potential benefit of compounded topical analgesics as an adjunct therapy for managing neuropathic pain in patients with limited treatment options, and when conventional options may not be suitable.

PMID 42965422
阅读全文 →
PubMedFrontiers in pain research (Lausanne, Switzerland)2026-10-31

Use of NSAIDs in orthopedic pain management: a Delphi consensus promoted by the Italian Society of Orthopedics and Traumatology (SIOT).

Tranquilli Leali Paolo P, Di Martino Alberto A, Mercurio Michele M, Spinelli Maria Silvia MS et al.

Non-steroidal anti-inflammatory drugs (NSAIDs) are a cornerstone of pain management in orthopedics, yet significant variability persists in prescribing practices and adherence to guidelines. A two-round modified Delphi consensus was conducted under the coordination of a methodologist, involving a scientific board of seven members and a broader expert panel of orthopedic surgeons, anesthesiologists, and pharmacologists affiliated with the Italian Society of Orthopedics and Traumatology (SIOT). Twenty statements spanning four domains-NSAID mechanisms of action, perioperative pain management in elective surgery, traumatic pain, and non-oncological/oncological pain-were submitted for evaluation using a six-point Likert scale; consensus was defined as ≥75% of ratings concentrating within a single tertile. Of the 20 statements, 12 reached consensus in the first round; six revised statements reached consensus in the second round; and two were eliminated because of persistent opinion dispersion. Final recommendations endorse short-cycle NSAID therapy (7-10 days) within multimodal analgesia, support the use of symptomatic slow-acting drugs for osteoarthritis to reduce NSAID consumption in osteoarthritis, recommend NSAIDs perioperatively in frail fracture patients to limit opioid use and delirium, identify ketoprofen lysine salt as having a favorable risk-benefit profile for postdischarge pain, and emphasize individualized NSAID selection based on cardiovascular, renal, and antiplatelet risk factors. This SIOT consensus provides evidence-informed, clinically actionable recommendations for NSAID use across the principal orthopedic pain scenarios, aiming to improve prescribing appropriateness and patient safety in routine practice.

PMID 42964588
阅读全文 →
PubMedCureus2026-10-30

Impact of Morphine on Early Recovery After Anterior Cruciate Ligament Reconstruction: A Case-Control Study.

Moussa Mohamad K MK, Mrabet Fethi F, Valentin Eugénie E, Grimaud Olivier O et al.

Effective pain management is crucial in postoperative recovery after Anterior Cruciate Ligament Reconstruction (ACLR). To examine the effectiveness of the new opioid-containing protocol compared to another previously published protocol based on Nefopam and dynamic compression cryotherapy. This retrospective analysis of prospectively collected data was conducted at a sports surgery center between 2023 and 2024, including 1116 patients undergoing primary isolated ACLR. Patients were divided into two matched groups based on postoperative pain management: the opioid group (N=556), treated with oral morphine sulfate (Actiskenan®) as needed in addition to multimodal analgesia (e.g., paracetamol, nefopam, and ketoprofen), and the non-opioid group N=556, treated with multimodal analgesia alone. Patients were matched for age, sex, BMI, Lysholm score, Tegner score, meniscal injury, and chondropathy. The primary outcome was pain on the visual analogue scale (VAS) in the early postoperative period, analyzed in relation to the minimal clinically important difference (MCID) and the patient acceptable symptom state (PASS) thresholds for VAS. The secondary outcome was side effects, including nausea, dizziness, vomiting, anxiety, and abdominal pain, as well as early complications and revision rate. The mean age in both groups was comparable (32.2 ± 9.4 years in the non-opioid group [N = 556] and 32.5 ± 10.0 years in the opioid group [N = 556], p = 0.867). Both groups predominantly used the quadrupled hamstring graft technique (440/556, 80.0% vs. 438/556, 79.9%, p = 0.4455). Preoperative scores were similar (p > 0.05). Postoperative pain was higher in the non-opioid group: day 0 VAS scores were 5.6 ± 2.7 (n = 536/556) vs. 5.3 ± 2.7 (n = 522/556) (p = 0.0339), and night pain was more common (379/556, 68.2% vs. 341/556, 61.3%, p = 0.0202). This trend continued on day 1 (5.2 ± 2.4 [n = 545/556] vs. 4.8 ± 2.4 [n = 543/556], p = 0.0014), day 2 (4.5 ± 2.4 [n = 551/556] vs. 4.2 ± 2.3 [n = 550/556], p = 0.0182), and day 3 (3.8 ± 2.3 [n = 551/556] vs. 3.4 ± 2.2 [n = 551/556], p = 0.0080). The non-opioid group had higher rates of dizziness on day 0 (100/536, 18.7% vs. 70/522, 13.4%, p = 0.0236). There was a trend toward higher complications in the non-opioid group (11/556, 2.0% vs. 3/556, 0.5%, p = 0.0558), mainly due to Cyclops syndrome and knee stiffness. Reoperation rates were similar (p > 0.05). Adding morphine to the postoperative protocol was associated with reduced postoperative pain in the first 3 days postoperatively and dizziness on the first day. However, while statistically significant, the mean difference in VAS scores did not exceed the MCID.

PMID 42959591
阅读全文 →
PubMedEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V2026-10-29

Impact of phosphate buffer strength and unbuffered water on ionizable drug powder dissolution.

Patel Roshni P RP, Polli James E JE

We are unaware of prior reports of the dependence of drug powder dissolution on buffer strength. The objective was to assess the effect of 5, 10, 50, and 100 mM sodium phosphate concentration on in vitro particle dissolution of ionizable drugs. Three weakly acidic drugs (naproxen, piroxicam, and phenytoin) and one weakly basic drug (dipyridamole) were studied at different pH conditions. Dissolution was conducted using USP Apparatus II with a mini-paddle at 37 °C in 100 mL media. Overall, the effect on dissolution profile was modest, with the largest effect generally being between 5 mM phosphate and zero phosphate (i.e., unbuffered water). Hence, a secondary objective was to predict the dissolution of the four ionizable drugs into unbuffered water, as well as for ibuprofen, ketoprofen, indomethacin, haloperidol, and meloxicam. Predictions anticipated slower ionizable drug dissolution into unbuffered water. Overall, dissolution predictions into buffer were better using the transient pH film model that accounts for the changing solid-liquid interfacial pH during dissolution, than for the conventional z-factor film model.

PMID 42957101
阅读全文 →

注册免费账户还可查看另外 4740 篇文献

免费注册查看全部文献 →

了解更多ketoprofen